RxDoctor Payments Data

Conner Hosner, MD

Family Medicine · Tigard, ORNPI 1164982781

Payments from drug & device makers

$572in general payments, 2019–2025

Across 25 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Hydrocision, Inc.$199
  • Gilead$102
  • AbbVie$71
  • Novo Nordisk$45
  • Corcept Therapeutics$39
  • Endo Pharmaceuticals Inc.$38
  • plus $78 from 4 others

What the payments were for

  • Food & beverage$572100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$572 in reported general payments places this provider in the 80th percentile of 1,221 family medicine providers in Oregon.

See all family medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$5,303
Medicare patients
25
Services billed
155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$48,688
JardianceEmpagliflozin31$38,817
EliquisApixaban34$31,723
MounjaroTirzepatide17$24,815
JanuviaSitagliptin Phosphate22$23,194
XareltoRivaroxaban11$13,109
Spiriva RespimatTiotropium Bromide25$12,967
TrulicityDulaglutide13$11,994
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,025
Combivent RespimatIpratropium/Albuterol Sulfate11$5,293
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,249
Metoprolol Succinate85$1,439
Atorvastatin Calcium151$1,405
Pravastatin Sodium52$928
Levothyroxine Sodium91$879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$45$48,68841 claims
Lilly USA, LLCMounjaro, Trulicity$14$36,80930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,221 family medicine providers in Oregon.

Other family medicine in Tigard

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →